1.79
1.79 (0%)
As of Feb 14, 2025
Sutro Biopharma, Inc. [STRO]
Source:
Company Overview
Sutro Biopharma, Inc is an oncology company developing site-specific and novel-format antibody drug conjugates, or ADCs, enabled by our proprietary integrated cell-free protein synthesis platform, XpressCF , and our site-specific conjugation platform, XpressCF . We aim to design and develop therapeutics using the most relevant and potent modalities, including ADCs, bispecific ADCs, immunostimulatory ADCs, or iADCs, and dual conjugate ADCs, or ADC2s.
| Country | United States |
| Headquarters | south san francisco, california |
| Phone Number | (650) 881-6500 |
| Industry | manufacturing |
| CEO | William J. Newell |
| Website | www.sutrobio.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $62 |
| Operating Profit | $-238.5 |
| Net Income | $-227.5 |
| Net Cash | $121 |
Profit Ratios
| Gross Margin | $62 |
| Operating Margin | -384.3 |
| Profit as % of Revenues | -27.3% |
| Profit as % of Assets | -53% |
| Profit as % of Stockholder Equity | -510% |
Management Effectiveness
| Return on Equity | -510% |
| Return on Assets | -58.7% |
| Turnover Ratio | 14.5% |
| EBITA | $-238.5 |
Balance Sheet and Cash Flow Measures
| Total Assets | $387.2 |
| Total Liabilities | $342.6 |
| Operating Cash Flow | $-191.5 |
| Investing Cash Flow | $218.5 |
| Financing Cash Flow | $94.1 |
